Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tiprelestat - tiakis Biotech

Next Previous
X
Search
Drug Profile

Tiprelestat - tiakis Biotech

Alternative Names: Elafin

Latest Information Update: 14 Jun 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Proteo Biotech
  • Developer Duke University; MiGenTra Egypt; Rhein Minapharm Biogenetics; SRI International; Stanford University; tiakis Biotech
  • Class Anti-inflammatories; Antihypertensives; Antipsoriatics; Recombinant proteins
  • Mechanism of Action Leucocyte elastase inhibitors; Myeloblastin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pulmonary hypertension; Pulmonary arterial hypertension; Oesophageal cancer; Postoperative inflammation
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II COVID-19 respiratory infection; Myocardial reperfusion injury; Postoperative inflammation
  • Phase I Pulmonary arterial hypertension
  • No development reported Lung disorders; Lung transplant rejection

Most Recent Events

  • 03 May 2024 Tiakis Biotech completed a phase II COMCOVID trial for COVID-19 respiratory infection (In adults, In the elderly) in Germany (IV) (EudraCT2022-000714-33)
  • 28 Nov 2023 Phase-I clinical development in Pulmonary arterial hypertension (In volunteers, In adults) is ongoing in USA (SC) (tiakis Biotech pipeline, November 2023)
  • 28 Nov 2023 tiakis Biotech plans a phase II trial in Pulmonary arterial hypertension (tiakis Biotech pipeline, November 2023)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top